GPR141

Summary

GPR141 (G protein-coupled receptor 141, HGNC:19997) is a protein-coding gene on chromosome 7p14.1, encoding Probable G-protein coupled receptor 141 (Q7Z602). Orphan receptor.

GPR141 is a member of the rhodopsin family of G protein-coupled receptors (GPRs) (Fredriksson et al., 2003 [PubMed 14623098]).

Source: NCBI Gene 353345 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 2 total
• Druggable target: yes
• MANE Select transcript: NM_001381946

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19997
Approved symbol	GPR141
Name	G protein-coupled receptor 141
Location	7p14.1
Locus type	gene with protein product
Status	Approved
Aliases	PGR13
Ensembl gene	ENSG00000187037
Ensembl biotype	protein_coding
OMIM	609045
Entrez	353345

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 12 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000334425, ENST00000447769, ENST00000450180, ENST00000461610, ENST00000467202, ENST00000865010, ENST00000865011, ENST00000865012, ENST00000865013, ENST00000926309, ENST00000926310, ENST00000941213, ENST00000941214, ENST00000941215

RefSeq mRNA: 4 — MANE Select: NM_001381946 NM_001329993, NM_001329994, NM_001381946, NM_181791

CCDS: CCDS5451

Canonical transcript exons

ENST00000334425 — 3 exons

Exon	Start	End
ENSE00001335205	37740380	37743835
ENSE00001788388	37685460	37685583
ENSE00003920778	37683766	37683903

Expression profiles

Bgee: expression breadth ubiquitous, 120 present calls, max score 91.00.

FANTOM5 (CAGE): breadth broad, TPM avg 3.4380 / max 305.4553, expressed in 352 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
78182	3.4065	350
78181	0.0315	15

Top tissues by expression

130 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	91.00	gold quality
leukocyte	CL:0000738	90.84	gold quality
bone marrow	UBERON:0002371	89.93	gold quality
blood	UBERON:0000178	89.44	gold quality
bone marrow cell	CL:0002092	87.46	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.75	gold quality
granulocyte	CL:0000094	85.33	gold quality
vermiform appendix	UBERON:0001154	74.91	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	74.05	gold quality
gall bladder	UBERON:0002110	70.97	gold quality
spleen	UBERON:0002106	70.85	gold quality
smooth muscle tissue	UBERON:0001135	68.86	gold quality
placenta	UBERON:0001987	67.12	gold quality
lymph node	UBERON:0000029	66.51	gold quality
rectum	UBERON:0001052	66.28	gold quality
right coronary artery	UBERON:0001625	65.87	gold quality
upper lobe of left lung	UBERON:0008952	64.14	gold quality
lung	UBERON:0002048	62.43	gold quality
duodenum	UBERON:0002114	60.81	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	60.68	gold quality
right lung	UBERON:0002167	60.66	gold quality
tonsil	UBERON:0002372	58.36	gold quality
descending thoracic aorta	UBERON:0002345	57.27	gold quality
urinary bladder	UBERON:0001255	56.29	gold quality
omental fat pad	UBERON:0010414	56.05	gold quality
fallopian tube	UBERON:0003889	54.68	gold quality
mucosa of transverse colon	UBERON:0004991	54.45	gold quality
small intestine	UBERON:0002108	54.36	gold quality
left uterine tube	UBERON:0001303	54.17	gold quality
endometrium	UBERON:0001295	54.16	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.74

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 2)

• GPR141-NME8 locus had strong genetic effect on susceptibility to generalized periodontitis in Japanese individuals with history of smoking. identified suggestive loci for periodontitis in Japanese population. (PMID:25672891)
• G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis. (PMID:37204251)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpr141	ENSDARG00000077026
mus_musculus	Gpr141	ENSMUSG00000053101
rattus_norvegicus	Gpr141	ENSRNOG00000066332

Paralogs (7): GPR174 (ENSG00000147138), GPR146 (ENSG00000164849), GPR183 (ENSG00000169508), GPR151 (ENSG00000173250), RXFP3 (ENSG00000182631), GPR132 (ENSG00000183484), P2RY11 (ENSG00000244165)

Protein

Protein identifiers

Probable G-protein coupled receptor 141 — Q7Z602 (reviewed: Q7Z602)

Alternative names: G-protein coupled receptor PGR13

All UniProt accessions (2): C9JDP7, Q7Z602

UniProt curated annotations — full annotation on UniProt →

Function. Orphan receptor.

Subcellular location. Cell membrane.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (4): NP_001316922, NP_001316923, NP_001368875, NP_861456 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR047160	GP183-like	Family

Pfam: PF00001

UniProt features (19 total): topological domain 8, transmembrane region 7, glycosylation site 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z602-F1	81.63	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 5, 9

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 44 (showing top): GOBP_INFLAMMATORY_RESPONSE, TGANTCA_AP1_C, GOMF_STEROID_BINDING, GOMF_STEROL_BINDING, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GSE13887_HEALTHY_VS_LUPUS_RESTING_CD4_TCELL_UP, GOMF_LIPID_BINDING, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, GOBP_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOMF_OXYSTEROL_BINDING, GSE14415_ACT_TCONV_VS_ACT_NATURAL_TREG_DN, KMT2D_TARGET_GENES, PAX3_TARGET_GENES, PAX7_TARGET_GENES, SKIL_TARGET_GENES

GO Biological Process (3): inflammatory response (GO:0006954), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (3): G protein-coupled receptor activity (GO:0004930), oxysterol binding (GO:0008142), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
defense response	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
sterol binding	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

458 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPR141	RHO	P08100	714
GPR141	GPR88	Q9GZN0	648
GPR141	VN1R2	Q8NFZ6	531
GPR141	THAP5	Q7Z6K1	512
GPR141	TMEM171	Q8WVE6	504
GPR141	GPR148	Q8TDV2	447
GPR141	GPR135	Q8IZ08	439
GPR141	GPR139	Q6DWJ6	431
GPR141	GPR142	Q7Z601	421
GPR141	TACR3	P29371	408
GPR141	GPR52	Q9Y2T5	408
GPR141	GPR75	O95800	396
GPR141	MANSC1	Q9H8J5	391
GPR141	PILRA	Q9UKJ1	386
GPR141	P2RY1	P47900	385

IntAct

47 interactions, top by confidence:

A	B	Type	Score
GPR141	CTSD	psi-mi:“MI:0915”(physical association)	0.560
GPR141	DMWD	psi-mi:“MI:0915”(physical association)	0.560
GPR141		psi-mi:“MI:0915”(physical association)	0.560
GRN	GPR141	psi-mi:“MI:0915”(physical association)	0.560
GPR141	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
PRKN	GPR141	psi-mi:“MI:0915”(physical association)	0.560
GPR141	PMP22	psi-mi:“MI:0915”(physical association)	0.560
GPR141	TTR	psi-mi:“MI:0915”(physical association)	0.560
GPR141	WFS1	psi-mi:“MI:0915”(physical association)	0.560
GPR141	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
GPR141	RNF11	psi-mi:“MI:0915”(physical association)	0.560
GPR141	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
HTT	GPR141	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (27): CCNY (Affinity Capture-MS), TSPAN3 (Affinity Capture-MS), TSPAN6 (Affinity Capture-MS), TTYH3 (Affinity Capture-MS), STXBP3 (Affinity Capture-MS), PAG1 (Affinity Capture-MS), STX4 (Affinity Capture-MS), AHNAK (Affinity Capture-MS), COX1 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), NRAS (Affinity Capture-MS), ATP5B (Affinity Capture-MS), C19orf25 (Affinity Capture-MS), TSPAN6 (Affinity Capture-MS), CCNY (Affinity Capture-MS)

ESM2 similar proteins: D4A4Q2, O00398, O14626, O35881, P32250, P34996, P43657, P49652, P55085, P55086, P60019, Q15391, Q2HJA4, Q2NNR5, Q3SAG9, Q3SX17, Q3UJF0, Q3ZBK9, Q4G072, Q5ZI82, Q63645, Q6IYF8, Q6XCF2, Q7TQP0, Q7Z602, Q80Z39, Q8BFU7, Q8BG55, Q8BLG2, Q8BMC0, Q920A1, Q924T8, Q924T9, Q95KC3, Q95N02, Q96P68, Q99677, Q99JA4, Q99MT7, Q9BXC1

Diamond homologs: P32246, P35343, P48146, P51676, Q3T181, Q7TQP0, Q7Z602, P70612, Q810W6, Q86VZ1, A7YY44, F1MV99, F1R332, O00398, O08565, O08858, O35811, O42179, O55197, O60755, O62747, O88626, O88853, O93361, O97571, O97664, P0C7U4, P25116, P25930, P26824, P30558, P30935, P30936, P30938, P30975, P30992, P32250, P32745, P35344, P35383

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

958 predictions. Top by Δscore:

Variant	Effect	Δscore
7:37715703:T:G	acceptor_gain	1.0000
7:37697298:T:G	donor_gain	0.9900
7:37709675:A:AG	acceptor_gain	0.9900
7:37709675:ACTTT:A	acceptor_gain	0.9900
7:37709682:AT:A	acceptor_gain	0.9900
7:37719371:A:G	acceptor_gain	0.9900
7:37740374:CTCCA:C	acceptor_loss	0.9900
7:37740375:TCCAG:T	acceptor_loss	0.9900
7:37740376:CCA:C	acceptor_loss	0.9900
7:37740377:CAGG:C	acceptor_loss	0.9900
7:37740378:A:AG	acceptor_gain	0.9900
7:37740378:AGG:A	acceptor_loss	0.9900
7:37740379:G:GC	acceptor_loss	0.9900
7:37740379:G:GG	acceptor_gain	0.9900
7:37740379:GGT:G	acceptor_gain	0.9900
7:37740518:T:TA	acceptor_gain	0.9900
7:37683901:AAGG:A	donor_loss	0.9800
7:37683902:AGGTA:A	donor_loss	0.9800
7:37683903:GGT:G	donor_loss	0.9800
7:37683904:GTAA:G	donor_loss	0.9800
7:37709676:C:G	acceptor_gain	0.9800
7:37709683:T:G	acceptor_gain	0.9800
7:37709694:C:G	acceptor_gain	0.9700
7:37721995:G:GT	donor_gain	0.9700
7:37725095:T:TA	acceptor_gain	0.9700
7:37683904:G:GG	donor_gain	0.9600
7:37697294:G:GG	donor_gain	0.9600
7:37697343:A:G	donor_gain	0.9600
7:37740378:AGGT:A	acceptor_gain	0.9600
7:37740379:GGTG:G	acceptor_gain	0.9600

AlphaMissense

2029 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:37740636:G:C	W81C	0.994
7:37740636:G:T	W81C	0.994
7:37740799:A:C	S136R	0.992
7:37740801:T:A	S136R	0.992
7:37740801:T:G	S136R	0.992
7:37741219:A:C	S276R	0.992
7:37741221:C:A	S276R	0.992
7:37741221:C:G	S276R	0.992
7:37740811:T:A	W140R	0.991
7:37740811:T:C	W140R	0.991
7:37741204:A:C	S271R	0.991
7:37741206:T:A	S271R	0.991
7:37741206:T:G	S271R	0.991
7:37740634:T:A	W81R	0.990
7:37740634:T:C	W81R	0.990
7:37740655:T:A	C88S	0.990
7:37740656:G:A	C88Y	0.990
7:37740656:G:C	C88S	0.990
7:37740893:T:G	F167C	0.990
7:37740580:A:C	S63R	0.989
7:37740582:C:A	S63R	0.989
7:37740582:C:G	S63R	0.989
7:37740608:G:C	R72P	0.989
7:37740657:C:G	C88W	0.989
7:37740898:T:C	F169L	0.989
7:37740900:T:A	F169L	0.989
7:37740900:T:G	F169L	0.989
7:37740607:C:A	R72S	0.988
7:37740892:T:C	F167L	0.987
7:37740894:T:A	F167L	0.987

dbSNP variants (sampled 300 via entrez): RS1000012242 (7:37732472 A>G), RS1000058595 (7:37685859 A>G), RS1000074545 (7:37714067 C>A), RS1000084504 (7:37725659 A>G), RS1000150760 (7:37727512 C>T), RS1000182496 (7:37682234 A>G), RS1000183867 (7:37718803 C>T), RS1000356378 (7:37707899 C>T), RS1000387151 (7:37734277 G>A), RS1000406564 (7:37712404 A>G), RS1000443073 (7:37688092 C>T), RS1000516353 (7:37719948 G>T), RS1000541013 (7:37720265 G>C), RS1000608697 (7:37695864 G>T), RS1000625988 (7:37702355 T>C)

Disease associations

OMIM: gene MIM:609045 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001762_446	Obesity-related traits	4.000000e-06
GCST002781_2	Periodontitis	4.000000e-06
GCST004069_15	Cerebrospinal fluid AB1-42 levels	5.000000e-06
GCST004069_3	Cerebrospinal fluid AB1-42 levels	7.000000e-06
GCST009391_2062	Metabolite levels	6.000000e-07
GCST009391_659	Metabolite levels	4.000000e-07
GCST012081_3	Response to tofacitinib treatment (herpes zoster)	2.000000e-06
GCST012082_3	Response to tofacitinib treatment (herpes zoster)(time to event)	6.000000e-09
GCST012085_4	Response to tofacitinib treatment in psoriasis (herpes zoster)(time to event)	2.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0005117	CCL5 measurement
EFO:0004670	beta-amyloid 1-42 measurement
EFO:0010346	cholesteryl ester 18:3 measurement
EFO:0010496	hippuric acid measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523879 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with no pharmacology

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance	2
sodium arsenate	decreases expression, increases abundance	1
arsenite	increases abundance, decreases expression	1
monomethylarsonic acid	decreases expression	1
arsenic acid	decreases expression, increases abundance	1
CGP 52608	increases reaction, affects binding	1
monomethylarsonous acid	decreases expression	1
dimethylmonothioarsinic acid	decreases expression	1
Zoledronic Acid	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Cacodylic Acid	decreases expression	1
Nickel	decreases expression	1
Oxygen	increases expression	1
Ozone	affects expression, increases abundance	1
Thiram	decreases expression	1
Tretinoin	increases expression	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4883411	Binding	PRESTO-Tango GPCRome screening (GPR141)	Data for DCP probe UCSF924

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KX33	PathHunter CHO-K1 GPR141 beta-arrestin	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists